Objective: Parkinson’s disease (PD) patients are usually treated with L-dopa and/or dopaminergic agonists, which act by binding five types of dopaminergic receptors (DRD1–DRD5). Peripheral immune cells are known to express dopamine receptors on their membrane surface, and therefore they could be directly affected by the treatment. Regulatory cells are the main modulators of inflammation, but it is not clear whether dopaminergic treatment could affect their functions. While only regulatory T cells (Tregs) have been proved to express dopamine receptors, it is not known whether other regulatory cells such as CD8regs, regulatory B cells (Bregs), tolerogenic dendritic cells, and intermediate monocytes also express them. Methods: The expression of dopamine receptors in Tregs, CD8regs, Bregs, tolerogenic dendritic cells, and intermediate monocytes was herein evaluated. cDNA from 11 PD patients and 9 control subjects was obtained and analyzed. Results: All regulatory cell populations expressed the genes coding for dopamine receptors, and this expression was further corroborated by flow cytometry. These findings may allow us to propose regulatory populations as possible targets for PD treatment. Conclusions: This study opens new paths to deepen our understanding on the effect of PD treatment on the cells of the regulatory immune response.

1.
Lang
AE
,
Espay
AJ
.
Disease Modification in Parkinson’s Disease: Current Approaches, Challenges, and Future Considerations
.
Mov Disord
.
2018
May
;
33
(
5
):
660
77
.
[PubMed]
0885-3185
2.
Chao
Y
,
Wong
SC
,
Tan
EK
.
Evidence of inflammatory system involvement in Parkinson’s disease.
Biomed Res Int.
2014
;2014.
3.
Mosley
RL
,
Hutter-Saunders
JA
,
Stone
DK
,
Gendelman
HE
.
Inflammation and adaptive immunity in Parkinson’s disease
.
Cold Spring Harb Perspect Med
.
2012
Jan
;
2
(
1
):
a009381
.
[PubMed]
2157-1422
4.
Kannarkat
GT
,
Boss
JM
,
Tansey
MG
.
The role of innate and adaptive immunity in Parkinson’s disease
.
J Parkinsons Dis
.
2013
;
3
(
4
):
493
514
.
[PubMed]
1877-718X
5.
Rangel-Barajas
C
,
Coronel
I
,
Florán
B
.
Dopamine Receptors and Neurodegeneration
.
[Internet]
.
Aging Dis
.
2015
Oct
;
6
(
5
):
349
68
. Available from: http://www.aginganddisease.org/EN/10.14336/AD.2015.0330
[PubMed]
2152-5250
6.
Kustrimovic
N
,
Rasini
E
,
Legnaro
M
,
Marino
F
,
Cosentino
M
.
Expression of dopaminergic receptors on human CD4+ T lymphocytes: flow cytometric analysis of naive and memory subsets and relevance for the neuroimmunology of neurodegenerative disease
.
J Neuroimmune Pharmacol
.
2014
Jun
;
9
(
3
):
302
12
.
[PubMed]
1557-1890
7.
Kustrimovic
N
,
Rasini
E
,
Legnaro
M
,
Bombelli
R
,
Aleksic
I
,
Blandini
F
, et al
Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson’s Disease
.
Sci Rep
.
2016
Sep
;
6
(
January
):
33738
.
[PubMed]
2045-2322
8.
Cosentino
M
,
Zaffaroni
M
,
Legnaro
M
,
Bombelli
R
,
Schembri
L
,
Baroncini
D
, et al
Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis
.
J Neuroimmunol
.
2016
Sep
;
298
:
82
9
.
[PubMed]
0165-5728
9.
Ostadali
MR
,
Ahangari
G
,
Eslami
MB
,
Razavi
A
,
Zarrindast
MR
,
Ahmadkhaniha
HR
, et al
The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR
.
Iran J Allergy Asthma Immunol
.
2004
Dec
;
3
(
4
):
169
74
.
[PubMed]
1735-1502
10.
McKenna
F
,
McLaughlin
PJ
,
Lewis
BJ
,
Sibbring
GC
,
Cummerson
JA
,
Bowen-Jones
D
, et al
Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study
.
J Neuroimmunol
.
2002
Nov
;
132
(
1-2
):
34
40
.
[PubMed]
0165-5728
11.
Besser
MJ
,
Ganor
Y
,
Levite
M
.
Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both
.
J Neuroimmunol
.
2005
Dec
;
169
(
1-2
):
161
71
.
[PubMed]
0165-5728
12.
Levite
M
,
Chowers
Y
,
Ganor
Y
,
Besser
M
,
Hershkovits
R
,
Cahalon
L
.
Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function
.
Eur J Immunol
.
2001
Dec
;
31
(
12
):
3504
12
.
[PubMed]
0014-2980
13.
Watanabe
Y
,
Nakayama
T
,
Nagakubo
D
,
Hieshima
K
,
Jin
Z
,
Katou
F
, et al
Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3
.
J Immunol
.
2006
Jan
;
176
(
2
):
848
56
.
[PubMed]
0022-1767
14.
Saha
B
,
Mondal
AC
,
Basu
S
,
Dasgupta
PS
.
Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis
.
Int Immunopharmacol
.
2001
Jul
;
1
(
7
):
1363
74
.
[PubMed]
1567-5769
15.
Nakano
K
,
Higashi
T
,
Takagi
R
,
Hashimoto
K
,
Tanaka
Y
,
Matsushita
S
.
Dopamine released by dendritic cells polarizes Th2 differentiation
.
Int Immunol
.
2009
Jun
;
21
(
6
):
645
54
.
[PubMed]
0953-8178
16.
Vignali
DA
,
Collison
LW
,
Workman
CJ
.
How regulatory T cells work
.
Nat Rev Immunol
.
2008
Jul
;
8
(
7
):
523
32
.
[PubMed]
1474-1733
17.
Liu
J
,
Gong
N
,
Huang
X
,
Reynolds
AD
,
Mosley
RL
,
Gendelman
HE
.
Neuromodulatory activities of CD4+CD25+ regulatory T cells in a murine model of HIV-1-associated neurodegeneration
.
J Immunol
.
2009
Mar
;
182
(
6
):
3855
65
.
[PubMed]
0022-1767
18.
Reynolds
AD
,
Banerjee
R
,
Liu
J
,
Gendelman
HE
,
Mosley
RL
.
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
.
J Leukoc Biol
.
2007
Nov
;
82
(
5
):
1083
94
.
[PubMed]
0741-5400
19.
Reynolds
AD
,
Stone
DK
, Hutter J a L, Benner EJ, Lee R, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease Ashley.
2011
;184(5):2261–71.
20.
Huang
Y
,
Liu
Z
,
Cao
BB
,
Qiu
YH
,
Peng
YP
.
Treg Cells Protect Dopaminergic Neurons against MPP+ Neurotoxicity via CD47-SIRPA Interaction
.
Cell Physiol Biochem
.
2017
;
41
(
3
):
1240
54
.
[PubMed]
1015-8987
21.
Johnston
LC
,
Su
X
,
Maguire-Zeiss
K
,
Horovitz
K
,
Ankoudinova
I
,
Guschin
D
, et al
Human interleukin-10 gene transfer is protective in a rat model of Parkinson’s disease
.
Mol Ther
.
2008
Aug
;
16
(
8
):
1392
9
.
[PubMed]
1525-0016
22.
Tesseur
I
,
Nguyen
A
,
Chang
B
,
Li
L
,
Woodling
NS
,
Wyss-Coray
T
, et al
Deficiency in Neuronal TGF-β Signaling Leads to Nigrostriatal Degeneration and Activation of TGF-β Signaling Protects against MPTP Neurotoxicity in Mice
.
J Neurosci
.
2017
Apr
;
37
(
17
):
4584
92
.
[PubMed]
0270-6474
23.
Cosentino
M
,
Zaffaroni
M
,
Trojano
M
,
Giorelli
M
,
Pica
C
,
Rasini
E
, et al
Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy
.
Neuroimmunomodulation
.
2012
;
19
(
5
):
283
92
.
[PubMed]
1021-7401
24.
Blair
PA
,
Noreña
LY
,
Flores-Borja
F
,
Rawlings
DJ
,
Isenberg
DA
,
Ehrenstein
MR
, et al
CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients
.
Immunity
.
2010
Jan
;
32
(
1
):
129
40
.
[PubMed]
1074-7613
25.
Hu
D
,
Weiner
HL
,
Ritz
J
.
Identification of cytolytic CD161- CD56+ regulatory CD8 T cells in human peripheral blood
.
PLoS One
.
2013
;
8
(
3
):
e59545
.
[PubMed]
1932-6203
26.
Ziegler-Heitbrock
L
,
Hofer
TP
.
Toward a refined definition of monocyte subsets
.
Front Immunol
.
2013
Feb
;
4
:
23
.
[PubMed]
1664-3224
27.
Flórez-Grau
G
,
Zubizarreta
I
,
Cabezón
R
,
Villoslada
P
,
Benitez-Ribas
D
.
Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials
.
Front Immunol
.
2018
May
;
9
:
1169
.
[PubMed]
1664-3224
28.
Cosentino
M
,
Fietta
AM
,
Ferrari
M
,
Rasini
E
,
Bombelli
R
,
Carcano
E
, et al
Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop
.
Blood
.
2007
Jan
;
109
(
2
):
632
42
.
[PubMed]
0006-4971
29.
Rollin Brant
. Power/Sample Size Calculator [Internet]. [cited 2019 May 18]. Available from: https://www.stat.ubc.ca/~rollin/stats/ssize/n2.html
30.
Niwa
F
,
Kuriyama
N
,
Nakagawa
M
,
Imanishi
J
.
Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson’s disease
.
Geriatr Gerontol Int
.
2012
Jan
;
12
(
1
):
102
7
.
[PubMed]
1444-1586
31.
Sinclair
D
,
Purves-Tyson
TD
,
Allen
KM
,
Weickert
CS
.
Impacts of stress and sex hormones on dopamine neurotransmission in the adolescent brain
.
Psychopharmacology (Berl)
.
2014
Apr
;
231
(
8
):
1581
99
.
[PubMed]
0033-3158
32.
Wooten
GF
,
Currie
LJ
,
Bovbjerg
VE
,
Lee
JK
,
Patrie
J
.
Are men at greater risk for Parkinson’s disease than women?
J Neurol Neurosurg Psychiatry
.
2004
Apr
;
75
(
4
):
637
9
.
[PubMed]
0022-3050
33.
Pacheco
R
,
Prado
CE
,
Barrientos
MJ
,
Bernales
S
.
Role of dopamine in the physiology of T-cells and dendritic cells
.
J Neuroimmunol
.
2009
Nov
;
216
(
1-2
):
8
19
.
[PubMed]
0165-5728
34.
Mukherjee
R
,
Kanti Barman
P
,
Kumar Thatoi
P
,
Tripathy
R
,
Kumar Das
B
,
Ravindran
B
.
Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous
.
Sci Rep
.
2015
Sep
;
5
(
1
):
13886
.
[PubMed]
2045-2322
35.
Coley
JS
,
Calderon
TM
,
Gaskill
PJ
,
Eugenin
EA
,
Berman
JW
.
Dopamine increases CD14+CD16+ monocyte migration and adhesion in the context of substance abuse and HIV neuropathogenesis
.
PLoS One
.
2015
Feb
;
10
(
2
):
e0117450
.
[PubMed]
1932-6203
36.
Skrzeczyńska-Moncznik
J
,
Bzowska
M
,
Loseke
S
,
Grage-Griebenow
E
,
Zembala
M
,
Pryjma
J
.
Peripheral blood CD14high CD16+ monocytes are main producers of IL-10
.
Scand J Immunol
.
2008
Feb
;
67
(
2
):
152
9
.
[PubMed]
0300-9475
37.
Levite
M
.
Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases
.
Acta Physiol (Oxf)
.
2016
Jan
;
216
(
1
):
42
89
.
[PubMed]
1748-1708
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.